Valuation : Sorrento Therapeutics, Inc.

Market Cap 67.15M 57.91M 54.49M 49.68M 93.28M 6.38B 93.96M 646M 251M 3.24B 252M 247M 10.75B P/E 2021
-3.2x
P/E 2022 -0.65x
Enterprise Value 152M 131M 123M 112M 211M 14.4B 212M 1.46B 566M 7.32B 569M 557M 24.29B EV / Sales 2021
29.1x
EV / Sales 2022 7.89x
Free-Float
98.65%
Yield 2021 *
-
Yield 2022 -
1 day+20.00%
1 week-25.00%
Current month+20.00%
1 month+20.00%
3 months+20.00%
6 months-62.50%
Current year-76.92%
1 week 0
Extreme 0.0004
0
1 month 0
Extreme 0.0004
0.01
Current year 0
Extreme 1.0E-6
0.01
1 year 0
Extreme 1.0E-6
0.1
3 years 0
Extreme 1.0E-6
0.25
5 years 0
Extreme 1.0E-6
9.31
10 years 0
Extreme 1.0E-6
19.39
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2011
Chief Tech/Sci/R&D Officer - 01/03/2022
General Counsel - -
Director TitleAgeSince
Chairman 61 01/08/2017
Date Insider Type Main position Quantity % Market Cap. Importance
3/17/23 A Option

Chief Executive Officer

19,695 0.0042%
12/15/22 A Free

Chief Executive Officer

1,500,000 0.3179%
12/2/22 A Option

Chief Executive Officer

505 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+20.00%-25.00%-90.00%-99.55% 272K
-0.25%-0.92%+49.47%+89.45% 68.13B
+1.21%+2.55%+46.72%+90.66% 63.6B
+1.31%+1.81%+49.04%+12.07% 25.57B
-0.25%-1.99%-10.72%+455.09% 26.6B
+0.33%-9.64%+1.95%-15.70% 25.52B
-6.09%-11.19%+224.80%+351.08% 18.23B
+1.18%+1.66%+35.20%-18.67% 19.69B
-1.49%-6.35%+7.84%+540.26% 15.16B
+4.12%+4.29%+52.03%+154.09% 13.54B
Average +2.01%-6.79%+36.63%+155.88% 27.6B
Weighted average by Cap. +0.15%-2.87%+47.00%+145.57%

Financials

2021 2022
Net sales 52.9M 45.63M 42.93M 39.14M 73.49M 5.02B 74.03M 509M 198M 2.55B 199M 194M 8.47B 62.84M 54.19M 50.99M 46.49M 87.29M 5.97B 87.93M 604M 235M 3.03B 236M 231M 10.06B
Net income -428M -369M -348M -317M -595M -40.67B -599M -4.12B -1.6B -20.67B -1.61B -1.57B -68.6B -573M -494M -465M -424M -796M -54.39B -802M -5.51B -2.14B -27.65B -2.15B -2.1B -91.74B
Net Debt 111M 95.47M 89.82M 81.89M 154M 10.51B 155M 1.06B 413M 5.34B 416M 407M 17.73B 84.53M 72.9M 68.59M 62.53M 117M 8.02B 118M 813M 316M 4.08B 317M 310M 13.54B
Logo Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. It is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.
Employees
949
Date Price Change Volume
01/09/26 $0.000600 +20.00% 88,266
31/08/26 $0.000500 0.00% 26,838
28/08/26 $0.000500 0.00% 26,750
27/08/26 $0.000500 -44.44% 103,292
26/08/26 $0.000900 +28.57% 135,982
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SRNE Stock